| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.zenotechlabs.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 332.62 Cr. | |
| Earnings per share (EPS) | 0.44 | Trailing Twelve Months Ending 2021-06 |
| Price-Earning Ratio (PE) | 124.34 | Trailing Twelve Months Ending 2021-06 |
| Industry PE | 35.25 | Trailing Twelve Months Ending 2021-06 |
| Book Value / Share | 8.51 | Trailing Twelve Months Ending 2021-06 |
| Price to Book Value | 6.41 | Calculated using Price: 54.50 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 6.10 Cr. | 61,030,568 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world. The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy. Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells. Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets. Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets. Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies. Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery. Product range of the company includes: Generics -- Biological
Chemical
New biologicals Zenotech develops new biological entities in the areas of
|
||
Company Profile
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.
The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.
Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.
Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.
Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.
Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.
Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.
Product range of the company includes:
Generics -- Biological
Chemical
New biologicals Zenotech develops new biological entities in the areas of
| 1 Day |
|
+4.91% |
| 1 Week |
|
+12.60% |
| 1 Month |
|
+35.40% |
| 3 Month |
|
+17.33% |
| 6 Month |
|
+78.10% |
| 1 Year |
|
+130.93% |
| 2 Year |
|
+224.40% |
| 5 Year |
|
+32.93% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | -18.08 | -65.67 | -155.73 | -7.73 | 24.35 | |||||
| Return on Capital Employed (%) | -15.98 | -48.47 | -39.28 | -61.52 | -65.68 | -61.88 | -5.95 | 18.32 | ||
| Return on Assets (%) | -14.54 | -37.69 | -33.32 | -45.43 | -32.82 | -38.33 | -17.89 | -3.76 | 12.67 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 52 | 26 | 3 | -27 | -46 | -66 | 42 | 39 | 50 | |
| Non Curr. Liab. | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Curr. Liab. | 16 | 40 | 66 | 91 | 99 | 116 | 39 | 45 | 35 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 68 | 67 | 70 | 64 | 53 | 51 | 82 | 85 | 86 | |
| Non Curr. Assets | 66 | 62 | 59 | 55 | 50 | 49 | 50 | 65 | 80 | |
| Curr. Assets | 3 | 5 | 11 | 8 | 3 | 2 | 31 | 19 | 6 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 68 | 67 | 70 | 64 | 53 | 51 | 82 | 85 | 86 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 2 | 3 | 3 | 4 | 2 | 2 | 11 | 13 | 26 | |
| Other Income | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 5 | 1 | |
| Total Income | 2 | 3 | 5 | 4 | 2 | 2 | 14 | 18 | 27 | |
| Total Expenditure | -7 | -24 | -20 | -24 | -10 | -13 | -19 | -17 | -17 | |
| PBIDT | -5 | -21 | -15 | -20 | -8 | -10 | -6 | 1 | 10 | |
| Interest | -1 | -1 | -5 | -7 | -8 | -8 | -2 | 0 | -1 | |
| Depreciation | -3 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -5 | |
| Taxation | ||||||||||
| Exceptional Items | -2 | 2 | 6 | |||||||
| PAT | -10 | -26 | -23 | -30 | -19 | -20 | -12 | -3 | 11 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | -10 | -24 | -8 | -5 | 2 | -16 | -14 | 11 | |
| Cash Fr. Inv. | 0 | 0 | -1 | 0 | 6 | -1 | -3 | -16 | -21 | |
| Cash Fr. Finan. | 2 | 10 | 30 | 7 | -1 | -1 | 47 | 15 | -3 | |
| Net Change | 0 | 0 | 5 | -1 | 0 | 0 | 28 | -15 | -12 | |
| Cash & Cash Eqvt | 2 | 2 | 6 | 6 | 0 | 0 | 28 | 13 | 1 |
|
Sat, 24 Jul 2021
Approval Of Unaudited Financial Results Of The Company For The Quarter Ended June 30 2021 Pursuant to the provisions of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday July 24 2021 have duly approved and took on record the Unaudited Standalone Financial Results of the Company for the quarter ended June 30 2021 which are enclosed herewith along with the Limited Review Report of the Statutory Auditors of the Company on Standalone Unaudited Financial Results for the quarter ended June 30 2021. The meeting of the Board of Directors of the Company commenced at 11:00 a.m. and concluded at 3:30 p.m. We request you to take the above on record. |
|
Sat, 17 Jul 2021
Board Meeting Intimation for Considering And Approving Inter-Alia The Unaudited Standalone Financial Results Of The Company For The Quarter Ended June 30 2021. ZENOTECH LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2021 inter alia to consider and approve the Unaudited Standalone Financial Results of the Company for the quarter ended June 30 2021. |
|
Mon, 12 Jul 2021
Shareholding for the Period Ended June 30 2021 Zenotech Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
| Mon, 26 Jul 2021 |
Stock Outperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Outperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Outperforming Benchmark Index
|
Strongly Outperforming Sectoral Index
|
Increasing Relative Strength - Sectoral Index
|
Equities
M.F.
Sectors